Takamori, Shinkichi
Shimokawa, Mototsugu
Komiya, Takefumi
Article History
Received: 14 May 2023
Accepted: 9 July 2023
First Online: 21 July 2023
Declarations
:
: Takefumi Komiya received institutional research funding from Merck and Gilead and advisory fees from Regeneron and Novocure. All authors declare no conflicts of interest associated with this study.
: Based on the use of only de-identified data, the study was exempted by the Parkview institutional review board.